Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

169
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
169
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

362
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
362
Statistical Inference Techniques in Hypothesis Testing: Parametric Versus Nonparametric Data01:16

Statistical Inference Techniques in Hypothesis Testing: Parametric Versus Nonparametric Data

407
Statistical inference techniques, paramount in hypothesis testing, differentiate into two broad categories: parametric and nonparametric statistics.
Parametric statistics, as the name suggests, assumes that data follow a specific distribution, often a normal distribution. This assumption enables robust hypothesis testing and estimation. Parametric methods, like the Student's t-test or Goodness-of-fit test, are frequently employed in biostatistics due to their robustness. For instance,...
407
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

518
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
518
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

514
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
514
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

198
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
198

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A General Framework for Designing and Evaluating Active-Controlled Trials with Non-Inferiority Objectives.

Statistics in medicine·2026
Same author

Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccine.

NPJ vaccines·2026
Same author

Profiling of SARS-CoV-2 virus shedding, antibody neutralization, and T-cell receptor repertoires in a large, multi-center cohort of young adults with varied prior exposures.

Frontiers in immunology·2026
Same author

Comparing HIV Vaccine Immunogenicity Across Trials With Different Populations and Study Designs.

Statistics in medicine·2026
Same author

Reflections on FDA Draft Guidance on Bayesian Methods in Trials-Protecting Scientific Integrity and Evidentiary Standards.

JAMA·2026
Same author

Estimating Risk Differences Using Large Healthcare Data Networks for Medical Product Post-Market Safety Outcomes in a Distributed Data Setting and Allowing for Active Post-Market Surveillance.

Statistics in medicine·2026

Related Experiment Video

Updated: Jan 3, 2026

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K

Statistical inference for net benefit measures in biomarker validation studies.

Tracey L Marsh1, Holly Janes1, Margaret S Pepe1

  • 1Fred Hutchinson Cancer Research Center, Seattle, Washington.

Biometrics
|November 17, 2019
PubMed
Summary

This study introduces methods to evaluate biomarker strategies using net benefit measures before large clinical trials. These statistical approaches help determine a biomarker's potential clinical impact and guide further research.

Keywords:
biomarkerclinical decision ruleclinical impactclinical utilityrisk prediction

More Related Videos

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
09:35

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

18.2K
Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

16.1K

Related Experiment Videos

Last Updated: Jan 3, 2026

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
09:35

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

18.2K
Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

16.1K

Area of Science:

  • Biostatistics
  • Biomarker Research
  • Clinical Trial Design

Background:

  • Referral strategies using risk scores and medical tests are common but difficult to assess early in biomarker research.
  • Direct clinical utility assessment requires implementation, which is not feasible in early biomarker phases.
  • Net benefit measures offer a way to assess potential clinical impact before late-phase studies.

Purpose of the Study:

  • To establish distribution theory for empirical net benefit estimators.
  • To propose empirical variance estimators for net benefit.
  • To provide methods for assessing biomarker potential and guiding study design.

Main Methods:

  • Developed distribution theory for empirical net benefit estimators.
  • Proposed novel estimators for net benefit under stratified two-phase and categorically matched case-control sampling.
  • Presented results for common net benefit variants and estimation from right-censored outcomes.

Main Results:

  • Established distribution theory for empirical estimators of net benefit and proposed empirical variance estimators.
  • Provided methods applicable to cohort and unmatched case-control samples, including point estimates and net benefit curves.
  • Developed novel estimators for stratified two-phase and categorically matched case-control sampling.

Conclusions:

  • The proposed statistical methods allow for the assessment of potential clinical impact of biomarkers early in research.
  • Net benefit measures, with confidence intervals, are crucial for deciding on further biomarker development and study design.
  • The methodology is demonstrated with lung cancer research examples, highlighting its utility in study design.